Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.

ABSTRACT:

Backgrounds

p53 is a tumor suppressor that prevents cancer onset and progression, and mutations in the p53 gene cause loss of the tumor suppressor function of the protein. The mutant p53 protein in tumor cells can form aggregates which contribute to the dominant-negative effect over the wild-type p53 protein, causing loss of p53 tumor suppression or gain of novel oncogenic functions. Mutations in p53 have been implicated in the pathogenesis of primary prostate cancer (PCa), and are often detected in recurrent and metastatic disease. Thus, targeting mutant p53 may constitute an alternative therapeutic strategy for advanced PCa for which there are no other viable options.

Methods

In this study, we used immunoprecipitation, immunofluorescence, clonogenic survival, and cell prol

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC7031025 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature